Your browser doesn't support javascript.
loading
FGF4 alleviates hyperglycemia in diabetes and obesity conditions.
Sundaram, Sivaraj M; Lenin, Raji Rajesh; Janardhanan, Rajiv.
Afiliación
  • Sundaram SM; Division of Medical Research, Faculty of Medical and Health Sciences, SRM Institute of Science and Technology, Kattankulathur 603 203, Chengalpattu District, Tamil Nadu, India. Electronic address: mss@srmist.edu.in.
  • Lenin RR; Division of Medical Research, Faculty of Medical and Health Sciences, SRM Institute of Science and Technology, Kattankulathur 603 203, Chengalpattu District, Tamil Nadu, India.
  • Janardhanan R; Division of Medical Research, Faculty of Medical and Health Sciences, SRM Institute of Science and Technology, Kattankulathur 603 203, Chengalpattu District, Tamil Nadu, India.
Trends Endocrinol Metab ; 34(10): 583-585, 2023 10.
Article en En | MEDLINE | ID: mdl-37625920
Increasing evidence suggests that the brain plays a key role in glucose homeostasis, making it a potential target for the treatment of type 2 diabetes (T2D). Sun et al. recently reported that intracerebroventricular (ICV) administration of a single dose of fibroblast growth factor 4 (FGF4) can induce sustained T2D remission in mouse models in the absence of any risk of hypoglycemia.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Hiperglucemia / Hipoglucemia Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Trends Endocrinol Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Hiperglucemia / Hipoglucemia Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Trends Endocrinol Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos